As of 2025-05-13, the EV/EBITDA ratio of Mirati Therapeutics Inc (MRTX) is -5.33. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. MRTX's latest enterprise value is 3,859.11 mil USD. MRTX's TTM EBITDA according to its financial statements is -723.54 mil USD. Dividing these 2 quantities gives us the above MRTX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 11.7x - 13.5x | 13.1x |
| Forward P/E multiples | 13.5x - 25.3x | 16.4x |
| Fair Price | (135.14) - (135.76) | (148.45) |
| Upside | -330.2% - -331.3% | -352.9% |
| Date | EV/EBITDA |